Breast hyperplasia
Fibrocystic breast disease is the most common breast disease in women, and its incidence ranks first among breast diseases. In recent years, the incidence of the disease has been increasing year by year, and the age of onset is getting younger and younger. Fibrocystic breast disease is the physiological proliferation and incomplete restoration of normal breast lobules, and the normal structure of the breast is disordered. It is a pathological hyperplasia. It is neither an inflammatory nor a tumor disease. It is more common in women aged 30-50, with the peak incidence at 35-40 years old.
-
Site of disease:
breast -
Infectious :
Not contagious -
Frequent population:
Women aged 30-50 -
Related symptoms:
Breast pain nodule cyst premenstrual breast pain axillary pain -
Concurrent disease:
Related Drugs
Rupikang Capsules
Manufacturer:
Shanxi Fusheng Gongda Pharmaceutical Co., Ltd.
Rukuaixiao soft capsules
Manufacturer:
Qingdao Double Whale Pharmaceutical Co., Ltd.
Xiaoru Sanjie Capsules
Manufacturer:
Shandong Buchang Shenzhou Pharmaceutical Co., Ltd.
Rupikang Capsules
Manufacturer:
Shandong Huinuo Pharmaceutical Co., Ltd.
Rukang soft capsule
Manufacturer:
Xi An Daheng Pharmaceutical Co., Ltd.
Ruhe Neixiao Tablets
Manufacturer:
Jilin Baiqi Pharmaceutical Co., Ltd.
Ruhe Neixiao Pills
Manufacturer:
Shuangshi Pharmaceutical Co., Ltd.
Prunella Vulgaris Oral Liquid
Manufacturer:
Guiyang Xintian Pharmaceutical Co., Ltd.
Rupiqing Tablets
Manufacturer:
Yunnan Tongda Biological Pharmaceutical Co., Ltd.
Breast core internal solution
Manufacturer:
Taiji Group Chongqing Tongjunge Pharmaceutical Co., Ltd.
Related Ingredients
-
Maltitol list
585-88-6 -
D(+)-Trehalose dihydrate list
6138-23-4 -
MYRRH GUM list
9000-45-7 -
OLIBANUM GUM list
8050-07-5